Literature DB >> 31732674

Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.

Manoj Kumar1, Kelley Salem1, Amye J Tevaarwerk2,3, Roberta M Strigel1,2,4, Amy M Fowler5,2,4.   

Abstract

Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer. PET using ER- and PR-specific radioligands enables a whole-body, noninvasive assessment of receptor expression. Recent investigations of ER imaging with 18F-fluoroestradiol have focused on diagnosing ER-positive metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit. Studies of PR imaging with 18F-fluorofuranyl norprogesterone have investigated how imaging changes in PR expression as a downstream target of ER activation may reflect an early response to ER-targeted therapy. This focused review highlights recent achievements in preclinical and clinical imaging of ER and PR in breast cancer.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET/CT; breast cancer; estrogen receptor; progesterone receptor

Mesh：

Substances：

Year:  2019        PMID： 31732674      PMCID： PMC8801958          DOI： 10.2967/jnumed.119.228858

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  31 in total

1.  Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.

Authors:  Ji Hyun Park; Myung Joo Kang; Jin-Hee Ahn; Jeong Eun Kim; Kyung Hae Jung; Gyungyub Gong; Hee Jin Lee; Byung-Ho Son; Sei-Hyun Ahn; Hak-Hee Kim; Hee Jung Shin; Dae-Hyuk Moon; Sung-Bae Kim
Journal:  Cancer Chemother Pharmacol       Date:  2016-08-04       Impact factor: 3.333

2.  Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Authors:  Clasina M Venema; Lemonitsa H Mammatas; Carolina P Schröder; Michel van Kruchten; Giulia Apollonio; Andor W J M Glaudemans; Alfons H H Bongaerts; Otto S Hoekstra; Henk M W Verheul; Epi Boven; Bert van der Vegt; Erik F J de Vries; Elisabeth G E de Vries; Ronald Boellaard; Catharina W Menke van der Houven van Oordt; Geke A P Hospers
Journal:  J Nucl Med       Date:  2017-09-14       Impact factor: 10.057

Review 3.  18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.

Authors:  Geraldine J Liao; Amy S Clark; Erin K Schubert; David A Mankoff
Journal:  J Nucl Med       Date:  2016-06-15       Impact factor: 10.057

4.  Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

Authors:  Michel van Kruchten; Elisabeth G de Vries; Andor W Glaudemans; Meta C van Lanschot; Martijn van Faassen; Ido P Kema; Myles Brown; Carolien P Schröder; Erik F de Vries; Geke A Hospers
Journal:  Cancer Discov       Date:  2014-11-07       Impact factor: 39.397

5.  Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.

Authors:  Michel Paquette; Éric Lavallée; Serge Phoenix; René Ouellet; Helena Senta; Johan E van Lier; Brigitte Guérin; Roger Lecomte; Éric E Turcotte
Journal:  J Nucl Med       Date:  2017-08-10       Impact factor: 10.057

6.  Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.

Authors:  Kelley Salem; Manoj Kumar; Kyle C Kloepping; Ciara J Michel; Yongjun Yan; Amy M Fowler
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

7.  18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Authors:  Hilde H Nienhuis; Michel van Kruchten; Sjoerd G Elias; Andor W J M Glaudemans; Erik F J de Vries; Alfons H H Bongaerts; Carolien P Schröder; Elisabeth G E de Vries; Geke A P Hospers
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

Review 8.  Clinical Potential of Estrogen and Progesterone Receptor Imaging.

Authors:  Hannah M Linden; Lanell M Peterson; Amy M Fowler
Journal:  PET Clin       Date:  2018-07

9.  Fluorine-18 Labeled Fluorofuranylnorprogesterone ([18F]FFNP) and Dihydrotestosterone ([18F]FDHT) Prepared by "Fluorination on Sep-Pak" Method.

Authors:  Falguni Basuli; Xiang Zhang; Burchelle Blackman; Margaret E White; Elaine M Jagoda; Peter L Choyke; Rolf E Swenson
Journal:  Molecules       Date:  2019-06-28       Impact factor: 4.411

10.  Sensitivity and Isoform Specificity of 18F-Fluorofuranylnorprogesterone for Measuring Progesterone Receptor Protein Response to Estradiol Challenge in Breast Cancer.

Authors:  Kelley Salem; Manoj Kumar; Yongjun Yan; Justin J Jeffery; Kyle C Kloepping; Ciara J Michel; Ginny L Powers; Aparna M Mahajan; Amy M Fowler
Journal:  J Nucl Med       Date:  2018-07-20       Impact factor: 10.057
View more
  8 in total

Review 1.  Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer.

Authors:  Hanyi Fang; Alessandra Cavaliere; Ziqi Li; Yiyun Huang; Bernadette Marquez-Nostra
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

2.  PET Imaging of Estrogen Receptors Using 18F-Based Radioligands.

Authors:  Manoj Kumar; Kelley Salem; Justin J Jeffery; Amy M Fowler
Journal:  Methods Mol Biol       Date:  2022

Review 3.  PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Authors:  John A Katzenellenbogen
Journal:  Cancers (Basel)       Date:  2020-07-23       Impact factor: 6.639

Review 4.  The role of estrogen receptor beta in breast cancer.

Authors:  Yujing Zhou; Xingdang Liu
Journal:  Biomark Res       Date:  2020-09-07

5.  Synthesis, stability, and cellular uptake of 131I-estradiol against MCF7 and T-47D human cell lines as a radioligand for binding assay.

Authors:  Isti Daruwati; Abednego Kristande Gwiharto; Ahmad Kurniawan; Isa Mahendra; Tri Hanggono Achmad; Mukh Syaifudin; Muchtaridi Muchtaridi
Journal:  Heliyon       Date:  2021-11-18

6.  Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors.

Authors:  Hina Dalal; Malin Dahlgren; Sergii Gladchuk; Christian Brueffer; Sofia K Gruvberger-Saal; Lao H Saal
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

7.  LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer.

Authors:  Kai Sun; Jing-Zhang Li; Zhan-Xiong Luo; Ri-Xin Chen
Journal:  Sci Rep       Date:  2022-08-30       Impact factor: 4.996

Review 8.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.